Muhammad Evy Prastiyanto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muhammad Evy Prastiyanto has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Sri Darmawati
Department of Medical Laboratory Technology, Faculty of Nursing and Health Science, Universitas Muhammadiyah Semarang. Jl. Kedungmundu Raya No. 18, Semarang 50273, Central Java, Indonesia
8 shared publicationsSri Sinto Dewi
Department of Medical Laboratory Technology, Faculty of Health and Nursing Sciences, Universitas Muhammadiyah Semarang. Jl. Kedungmundu Raya No. 18, Semarang 50273, Central Java, Indonesia
4 shared publicationsAfifah Khairunnisa
Department of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Universitas Muhammadiyah Semarang
3 shared publications- Afifah Khairunnisa
Department of Medical Laboratory Technology, Faculty of Health and Nursing Universitas Muhammadiyah Semarang Semarang Indonesia
3 shared publications Ana Hidayati Mukaromah
Graduate Program of Laboratory for Clinical Science, Faculty of Nursing and Health Sciences, Universitas Muhammadiyah Semarang. Jl. Kedungmundu Raya No. 18, Semarang 50273, Central Java, Indonesia
3 shared publicationsDeivan Pradana Putra
Department of Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Universitas Muhammadiyah Semarang
3 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (8)
Prevalence, Antimicrobial Resistance Profile, and Multidrug Resistance of Methicillin‐Resistant Staphylococcus aureus (MDR‐MRSA) in Clinical Isolates From Indonesian Healthcare Facility: A Cross‐Sectional Study
Background and Aims: Methicillin‐resistant Staphylococcus aureus (MRSA) is a significant pathogen associated with hospital‐acquired infections, with its global prevalence, including in Indonesia, steadily increasing. However, comprehensive data on MRSA prevalence and antimicrobial susceptibility within Indonesian hospital settings remain limited. This study aimed to assess the prevalence of MRSA and its antimicrobial susceptibility profile among clinical samples isolated from Indonesian patients. Methods: A cross‐sectional, descriptive‐analytic study was conducted over a 3‐year period (January 2022–December 2024). The study population consisted of clinical specimens obtained from both inpatients and outpatients recorded at the Microbiology Laboratory. MRSA isolates were identified using standard microbiological techniques, and antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The multidrug resistance (MDR) profile was determined based on resistance to at least three different antibiotic classes. Results: Among the clinical samples analyzed (279 S. aureus ), MRSA was detected in 258 (92.47%). The highest prevalence was observed in pus samples (77.8%). MRSA and methicillin‐sensitive S. aureus (MSSA) isolates exhibited high susceptibility to Quinupristin/Dalfopristin (98.1% and 100%), Linezolid (96.9% and 95.2%), Vancomycin (93% and 100%), Tigecycline (98.4% and 100%), Nitrofurantoin (98.4% and 100%), and Rifampicin (96.1% and 100%). MDR‐MRSA strains accounted for 55% of all MRSA isolates, a notably higher proportion compared to the 19% observed in MSSA. Conclusion: The study highlights a notable prevalence of MRSA and MDR‐MRSA among clinical isolates in Semarang, coupled with a concerning level of multidrug resistance. Although certain antibiotics remain effective against MRSA, the findings emphasize the necessity for continuous surveillance and antimicrobial stewardship programs. Strengthened infection control measures and optimized antibiotic management strategies are crucial to mitigating MRSA spread and preserving effective treatment options within Indonesian healthcare settings.
- 12 August 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (8)
Open AccessPrevalence, Antimicrobial Resistance Profile, and Multidrug Resistance of Methicillin‐Resistant Staphylococcus aureus (MDR‐MRSA) in Clinical Isolates From Indonesian Healthcare Facility: A Cross‐Sectional Study
Background and Aims: Methicillin‐resistant Staphylococcus aureus (MRSA) is a significant pathogen associated with hospital‐acquired infections, with its global prevalence, including in Indonesia, steadily increasing. However, comprehensive data on MRSA prevalence and antimicrobial susceptibility within Indonesian hospital settings remain limited. This study aimed to assess the prevalence of MRSA and its antimicrobial susceptibility profile among clinical samples isolated from Indonesian patients. Methods: A cross‐sectional, descriptive‐analytic study was conducted over a 3‐year period (January 2022–December 2024). The study population consisted of clinical specimens obtained from both inpatients and outpatients recorded at the Microbiology Laboratory. MRSA isolates were identified using standard microbiological techniques, and antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The multidrug resistance (MDR) profile was determined based on resistance to at least three different antibiotic classes. Results: Among the clinical samples analyzed (279 S. aureus ), MRSA was detected in 258 (92.47%). The highest prevalence was observed in pus samples (77.8%). MRSA and methicillin‐sensitive S. aureus (MSSA) isolates exhibited high susceptibility to Quinupristin/Dalfopristin (98.1% and 100%), Linezolid (96.9% and 95.2%), Vancomycin (93% and 100%), Tigecycline (98.4% and 100%), Nitrofurantoin (98.4% and 100%), and Rifampicin (96.1% and 100%). MDR‐MRSA strains accounted for 55% of all MRSA isolates, a notably higher proportion compared to the 19% observed in MSSA. Conclusion: The study highlights a notable prevalence of MRSA and MDR‐MRSA among clinical isolates in Semarang, coupled with a concerning level of multidrug resistance. Although certain antibiotics remain effective against MRSA, the findings emphasize the necessity for continuous surveillance and antimicrobial stewardship programs. Strengthened infection control measures and optimized antibiotic management strategies are crucial to mitigating MRSA spread and preserving effective treatment options within Indonesian healthcare settings.
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 7, 1847829
Shifting epidemiology and prevalence of methicillin-resistant Staphylococcus aureus in Indonesia: a systematic review and meta-analysis
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) remains a major contributor to antimicrobial resistance globally, yet national-level evidence in Indonesia is fragmented. This study aimed to estimate the pooled prevalence and evaluate the epidemiological distribution of MRSA across Indonesia. Methods: A systematic review and meta-analysis was conducted following PRISMA 2020 guidelines and registered in PROSPERO (CRD420261300013). PubMed, Scopus, Cochrane Library, and Garuda databases were searched for studies published between January 2000 and January 2026. Observational studies reporting MRSA prevalence in Indonesia were included. Data were extracted independently, and pooled prevalence estimates were calculated using a random-effects model. Heterogeneity and publication bias were assessed using I² statistics, Begg’s test, and Egger’s test. Results: A total of 24 studies comprising 4,920 Staphylococcus aureus isolates were included. The pooled prevalence of MRSA was 41% (95% CI: 27%–56%), indicating a substantial burden. Temporal analysis showed an increasing trend, with prevalence reaching 59% in recent years. Specimen-based analysis revealed the highest prevalence in respiratory tract samples (44%), followed by blood (37%) and wound specimens (25%). Regional disparities were observed, with higher prevalence in North Sumatra and several provinces outside Java. Heterogeneity was high across studies (I² > 99%), while no significant publication bias was detected. Conclusion: MRSA prevalence in Indonesia remains high and demonstrates sustained endemic transmission with regional variability. Strengthening antimicrobial stewardship, surveillance systems, and infection control strategies is essential to mitigate the growing burden of MRSA. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261300013.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 7, 1847829
Open AccessShifting epidemiology and prevalence of methicillin-resistant Staphylococcus aureus in Indonesia: a systematic review and meta-analysis
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) remains a major contributor to antimicrobial resistance globally, yet national-level evidence in Indonesia is fragmented. This study aimed to estimate the pooled prevalence and evaluate the epidemiological distribution of MRSA across Indonesia. Methods: A systematic review and meta-analysis was conducted following PRISMA 2020 guidelines and registered in PROSPERO (CRD420261300013). PubMed, Scopus, Cochrane Library, and Garuda databases were searched for studies published between January 2000 and January 2026. Observational studies reporting MRSA prevalence in Indonesia were included. Data were extracted independently, and pooled prevalence estimates were calculated using a random-effects model. Heterogeneity and publication bias were assessed using I² statistics, Begg’s test, and Egger’s test. Results: A total of 24 studies comprising 4,920 Staphylococcus aureus isolates were included. The pooled prevalence of MRSA was 41% (95% CI: 27%–56%), indicating a substantial burden. Temporal analysis showed an increasing trend, with prevalence reaching 59% in recent years. Specimen-based analysis revealed the highest prevalence in respiratory tract samples (44%), followed by blood (37%) and wound specimens (25%). Regional disparities were observed, with higher prevalence in North Sumatra and several provinces outside Java. Heterogeneity was high across studies (I² > 99%), while no significant publication bias was detected. Conclusion: MRSA prevalence in Indonesia remains high and demonstrates sustained endemic transmission with regional variability. Strengthening antimicrobial stewardship, surveillance systems, and infection control strategies is essential to mitigate the growing burden of MRSA. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261300013.
- Open Access
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 7, 1847898
National prevalence of carbapenem-resistance Pseudomonas aeruginosa in Indonesia: a systematic review and meta-analysis
Objective: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a critical priority pathogen associated with limited therapeutic options and increased morbidity and mortality. However, national-level evidence regarding CRPA prevalence in Indonesia remains fragmented. This study aimed to estimate the pooled prevalence and evaluate the epidemiological distribution of CRPA across Indonesia. Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines and registered in PROSPERO (CRD420261327390). PubMed, Scopus, Cochrane Library, and Garuda databases were searched for studies published between January 2001 and February 2026. Observational studies reporting CRPA prevalence in Indonesia were included. Data were extracted independently, and pooled prevalence estimates were calculated using a random-effects model. Heterogeneity and publication bias were assessed using I² statistics, Begg’s test, and Egger’s test. Results: A total of 16 studies comprising 3,852 Pseudomonas aeruginosa isolates were included. The pooled prevalence of CRPA was 43% (95% CI: 29%–58%), indicating a substantial burden. Subgroup analysis showed higher prevalence in combined regions (Yogyakarta, West Java, West Sumatra, Central Java, and Bali) (50%), followed by South Sulawesi (42%), East Java (40%), and Jakarta (37%). Spatial distribution demonstrated concentration of cases in East Java and major referral centers. Molecular analysis revealed diverse carbapenemase genes, predominantly bla IMP and bla VIM . Heterogeneity was high across studies (I² = 99.13%), while no significant publication bias was detected. Conclusion: CRPA prevalence in Indonesia is high and widely distributed with significant regional variability. Strengthening antimicrobial stewardship, expanding surveillance systems, and integrating molecular epidemiology are essential to control the spread of CRPA. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261327390.
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 7, 1847898
Open AccessNational prevalence of carbapenem-resistance Pseudomonas aeruginosa in Indonesia: a systematic review and meta-analysis
Objective: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a critical priority pathogen associated with limited therapeutic options and increased morbidity and mortality. However, national-level evidence regarding CRPA prevalence in Indonesia remains fragmented. This study aimed to estimate the pooled prevalence and evaluate the epidemiological distribution of CRPA across Indonesia. Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines and registered in PROSPERO (CRD420261327390). PubMed, Scopus, Cochrane Library, and Garuda databases were searched for studies published between January 2001 and February 2026. Observational studies reporting CRPA prevalence in Indonesia were included. Data were extracted independently, and pooled prevalence estimates were calculated using a random-effects model. Heterogeneity and publication bias were assessed using I² statistics, Begg’s test, and Egger’s test. Results: A total of 16 studies comprising 3,852 Pseudomonas aeruginosa isolates were included. The pooled prevalence of CRPA was 43% (95% CI: 29%–58%), indicating a substantial burden. Subgroup analysis showed higher prevalence in combined regions (Yogyakarta, West Java, West Sumatra, Central Java, and Bali) (50%), followed by South Sulawesi (42%), East Java (40%), and Jakarta (37%). Spatial distribution demonstrated concentration of cases in East Java and major referral centers. Molecular analysis revealed diverse carbapenemase genes, predominantly bla IMP and bla VIM . Heterogeneity was high across studies (I² = 99.13%), while no significant publication bias was detected. Conclusion: CRPA prevalence in Indonesia is high and widely distributed with significant regional variability. Strengthening antimicrobial stewardship, expanding surveillance systems, and integrating molecular epidemiology are essential to control the spread of CRPA. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261327390.
- 2 February 2026
- Published by Korean Society for Microbiology and Biotechnology in Microbiology and Biotechnology Letters
- Vol. 54 (2) , 1-17
Clinical Outcomes associated with Multidrug-Resistant Gram-Negative Bacterial Infections in Chronic Wound Infections: an Umbrella Review and Meta-analysis
Deivan Pradana Putra, Sri Sinto Dewi, and Muhammad Evy Prastiyanto. Microbiol. Biotechnol. Lett. 2026;54:1-17. https://doi.org/10.48022/mbl.2511.11010
- 2 February 2026
- Published by Korean Society for Microbiology and Biotechnology in Microbiology and Biotechnology Letters
- Vol. 54 (2) , 1-17
Clinical Outcomes associated with Multidrug-Resistant Gram-Negative Bacterial Infections in Chronic Wound Infections: an Umbrella Review and Meta-analysis
Deivan Pradana Putra, Sri Sinto Dewi, and Muhammad Evy Prastiyanto. Microbiol. Biotechnol. Lett. 2026;54:1-17. https://doi.org/10.48022/mbl.2511.11010
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 2987105
Emerging Multidrug‐Resistant Bacteria in Indonesian Neonatal Patients: Prevalence and Antimicrobial Resistance Profiles From Clinical Samples
Background: Neonatal sepsis poses a serious health challenge, especially with the increasing prevalence of multidrug‐resistant (MDR) bacteria among Indonesian neonates. This study examines the occurrence of MDR bacteria in clinical samples from neonates and analyzes their resistance patterns to enhance treatment strategies. Methods: From January 2022 to December 2024, a total of 223 bacterial isolates were gathered from neonatal patients with infections at Kanjeng Raden Mas Tumenggung Wongsonegoro Hospital in Semarang, Indonesia. The identification process commenced with Gram staining and assessment of colony morphology preceded by antibiotic susceptibility testing utilizing the VITEK2 Compact systems. Results: The study findings revealed a notable prevalence of MDR infections. Fecal samples accounted for 29.15% of the samples analyzed, with 63.1% exhibiting MDR characteristics. Blood samples, representing 24.66% of the samples, displayed a concerning MDR rate of 83.6%. Similarly, urine samples (24.66%) showed a MDR rate of 50.9%, while sputum samples (10.76%) presented a striking MDR classification of 91.7%. Key MDR rates were identified in Escherichia coli (45.6%), Staphylococcus spp. (70.4%), Klebsiella pneumoniae (71.9%), Acinetobacter spp. (63.6%), and Pseudomonas aeruginosa (100%). The overall prevalence of MDR infections was calculated at 66.40%, with significant resistance observed towards ampicillin (over 80%) in gram‐negative bacteria and benzylpenicillin (over 90%) in gram‐positive bacteria, particularly Staphylococcus spp. Conclusion: The findings underscore the urgent need for effective strategies to combat MDR infections in healthcare settings, emphasizing enhanced antibiotic management, tailored treatment protocols, and a more holistic and systematically structured research strategy for neonatal units in Indonesia.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1) , 2987105
Open AccessEmerging Multidrug‐Resistant Bacteria in Indonesian Neonatal Patients: Prevalence and Antimicrobial Resistance Profiles From Clinical Samples
Background: Neonatal sepsis poses a serious health challenge, especially with the increasing prevalence of multidrug‐resistant (MDR) bacteria among Indonesian neonates. This study examines the occurrence of MDR bacteria in clinical samples from neonates and analyzes their resistance patterns to enhance treatment strategies. Methods: From January 2022 to December 2024, a total of 223 bacterial isolates were gathered from neonatal patients with infections at Kanjeng Raden Mas Tumenggung Wongsonegoro Hospital in Semarang, Indonesia. The identification process commenced with Gram staining and assessment of colony morphology preceded by antibiotic susceptibility testing utilizing the VITEK2 Compact systems. Results: The study findings revealed a notable prevalence of MDR infections. Fecal samples accounted for 29.15% of the samples analyzed, with 63.1% exhibiting MDR characteristics. Blood samples, representing 24.66% of the samples, displayed a concerning MDR rate of 83.6%. Similarly, urine samples (24.66%) showed a MDR rate of 50.9%, while sputum samples (10.76%) presented a striking MDR classification of 91.7%. Key MDR rates were identified in Escherichia coli (45.6%), Staphylococcus spp. (70.4%), Klebsiella pneumoniae (71.9%), Acinetobacter spp. (63.6%), and Pseudomonas aeruginosa (100%). The overall prevalence of MDR infections was calculated at 66.40%, with significant resistance observed towards ampicillin (over 80%) in gram‐negative bacteria and benzylpenicillin (over 90%) in gram‐positive bacteria, particularly Staphylococcus spp. Conclusion: The findings underscore the urgent need for effective strategies to combat MDR infections in healthcare settings, emphasizing enhanced antibiotic management, tailored treatment protocols, and a more holistic and systematically structured research strategy for neonatal units in Indonesia.
- 5 August 2025
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 06, 1-14
A Bibliometric Analysis of the Prognostic Role of Proteomic Markers in Recurrent COVID-19 Infection
Introduction: The COVID-19 pandemic has presented unprecedented global challenges, with recurrent infections emerging as a significant concern in clinical and public health settings. Investigating the prognostic value of proteomic markers is crucial for enhancing understanding of disease recurrence, immune responses, and patient outcomes. This bibliometric analysis aimed to map the intellectual landscape, identify key contributors, and assess the impact of collaborative networks within this research domain. Methods: A comprehensive search was conducted in the Scopus database for publications on proteomic markers in recurrent COVID-19 infections from January 2020 to November 2024 using predefined search terms. Extracted data included countries, research disciplines, citation metrics, authorship networks, and keyword co-occurrences. Bibliometric mapping and network visualization were performed using VOSviewer to elucidate leading contributors, thematic clusters, and global research trends. Results: A total of 910 publications were retrieved, which revealed a peak in research on recurrent COVID-19 infections in 2021 (286 documents). The top 10 most-cited publications included those by Focosi D and Yassine HM (7 publications). Medicine was the most represented field, while neuroscience had the least number of publications (1.9%). Korber B emerged as the leading author with 2,823 citations. The USA and the UK were the top contributors to research on proteomic markers in recurrent COVID-19. “COVID-19” was the most frequently used keyword, and PNAS was the highestimpact journal (8 documents, 1,067 citations). The analysis also covers collaboration between coauthorship countries (United States, 247 documents, 12,967 citations, and a total link strength of 189) and citations by country (United States, 247 publications, 12,967 citations, and a link strength of 152). Discussion: Publication trends reflected a surge during the pandemic peak, driven by urgent global efforts to understand reinfections and immune mechanisms. The decline in publications post-2022 suggests a shift toward broader post-COVID-19 research topics. High-income countries dominated collaborative networks, whereas low- and middle-income regions were underrepresented, underscoring the need for more equitable global research participation. Conclusion: This study provides a comprehensive overview of the current literature, identifies research gaps, and suggests directions for future investigations of proteomic markers for predicting recurrent COVID-19 outcomes. These insights serve to support researchers and policymakers in advancing diagnostic, preventive, and therapeutic strategies for effectively managing recurrent infections.
- 5 August 2025
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 06, 1-14
A Bibliometric Analysis of the Prognostic Role of Proteomic Markers in Recurrent COVID-19 Infection
Introduction: The COVID-19 pandemic has presented unprecedented global challenges, with recurrent infections emerging as a significant concern in clinical and public health settings. Investigating the prognostic value of proteomic markers is crucial for enhancing understanding of disease recurrence, immune responses, and patient outcomes. This bibliometric analysis aimed to map the intellectual landscape, identify key contributors, and assess the impact of collaborative networks within this research domain. Methods: A comprehensive search was conducted in the Scopus database for publications on proteomic markers in recurrent COVID-19 infections from January 2020 to November 2024 using predefined search terms. Extracted data included countries, research disciplines, citation metrics, authorship networks, and keyword co-occurrences. Bibliometric mapping and network visualization were performed using VOSviewer to elucidate leading contributors, thematic clusters, and global research trends. Results: A total of 910 publications were retrieved, which revealed a peak in research on recurrent COVID-19 infections in 2021 (286 documents). The top 10 most-cited publications included those by Focosi D and Yassine HM (7 publications). Medicine was the most represented field, while neuroscience had the least number of publications (1.9%). Korber B emerged as the leading author with 2,823 citations. The USA and the UK were the top contributors to research on proteomic markers in recurrent COVID-19. “COVID-19” was the most frequently used keyword, and PNAS was the highestimpact journal (8 documents, 1,067 citations). The analysis also covers collaboration between coauthorship countries (United States, 247 documents, 12,967 citations, and a total link strength of 189) and citations by country (United States, 247 publications, 12,967 citations, and a link strength of 152). Discussion: Publication trends reflected a surge during the pandemic peak, driven by urgent global efforts to understand reinfections and immune mechanisms. The decline in publications post-2022 suggests a shift toward broader post-COVID-19 research topics. High-income countries dominated collaborative networks, whereas low- and middle-income regions were underrepresented, underscoring the need for more equitable global research participation. Conclusion: This study provides a comprehensive overview of the current literature, identifies research gaps, and suggests directions for future investigations of proteomic markers for predicting recurrent COVID-19 outcomes. These insights serve to support researchers and policymakers in advancing diagnostic, preventive, and therapeutic strategies for effectively managing recurrent infections.
- Open Access
- 26 June 2025
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 40 (2) , 101-109
TMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic Target
The transmembrane serine protease 2 (TMPRSS2) gene plays a crucial role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by priming the viral spike protein for membrane fusion and facilitating viral entry into host cells. This review aims to explore the molecular function of TMPRSS2, its genetic variations, and its potential as a therapeutic target in corona virus disease 2019 (COVID-19) and other respiratory viral infections. TMPRSS2 is highly expressed in lung and prostate tissues and is regulated by androgens, which may contribute to sex-based differences in COVID-19 severity. Genetic polymorphisms in TMPRSS2 have been been associated with variability in disease susceptibility and severity across populations. Several TMPRSS2 inhibitors, including serine protease inhibitors, such as camostat mesylate and nafamostat, have demonstarted promise in blocking viral entry. In addition, RNA based strategies such as siRNA and clustered regularly interspaced short palindromic repeats offer potential approaches for downregulating TMPRSS2 expression. However, the development of selective inhibitors that avoid off target effects remains a challenge. The presence of TMPRSS2-ERG gene fusion, commonly found in prostate cancer, has also been linked to altered COVID-19 susceptibility, suggesting a complex interplay between viral infection and cancer biology. This review also discusses future perspectives, including large-scale genomic studies to identify high-risk individuals, the development of next-generation TMPRSS2 inhibitors, and potential broad-spectrum antiviral therapies targeting TMPRSS2.
- 26 June 2025
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 40 (2) , 101-109
Open AccessTMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic Target
The transmembrane serine protease 2 (TMPRSS2) gene plays a crucial role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by priming the viral spike protein for membrane fusion and facilitating viral entry into host cells. This review aims to explore the molecular function of TMPRSS2, its genetic variations, and its potential as a therapeutic target in corona virus disease 2019 (COVID-19) and other respiratory viral infections. TMPRSS2 is highly expressed in lung and prostate tissues and is regulated by androgens, which may contribute to sex-based differences in COVID-19 severity. Genetic polymorphisms in TMPRSS2 have been been associated with variability in disease susceptibility and severity across populations. Several TMPRSS2 inhibitors, including serine protease inhibitors, such as camostat mesylate and nafamostat, have demonstarted promise in blocking viral entry. In addition, RNA based strategies such as siRNA and clustered regularly interspaced short palindromic repeats offer potential approaches for downregulating TMPRSS2 expression. However, the development of selective inhibitors that avoid off target effects remains a challenge. The presence of TMPRSS2-ERG gene fusion, commonly found in prostate cancer, has also been linked to altered COVID-19 susceptibility, suggesting a complex interplay between viral infection and cancer biology. This review also discusses future perspectives, including large-scale genomic studies to identify high-risk individuals, the development of next-generation TMPRSS2 inhibitors, and potential broad-spectrum antiviral therapies targeting TMPRSS2.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1) , 3743202
A Cross‐Sectional Study of Extended‐Spectrum β ‐Lactamase–Producing Escherichia coli Isolated From Clinical Samples: Single‐Center Investigation in Indonesia
The emergence of extended‐spectrum beta‐lactamase–producing Escherichia coli (ESBL‐producing E. coli ) is a significant public health concern, particularly in developing countries like Indonesia, where reports on the prevalence and characteristics of these resistant strains are scarce. This lack of data hampers effective infection control and antibiotic stewardship efforts. This study is aimed at investigating the prevalence and assessing the antimicrobial susceptibility profiles of ESBL‐producing E. coli isolated from clinical samples of Indonesian patients, thereby contributing to an understanding of antibiotic resistance patterns in this region. A cross‐sectional study was conducted at RSUD dr. Adhyatma Hospital, Semarang, Indonesia, over 3 years (from January 2022 to December 2024). Clinical specimens were obtained from patients diagnosed with E. coli infections, and isolates were identified and assessed for antibiotic susceptibility utilizing the VITEK2 Compact system. Data were examined via the Fisher’s exact test. Out of 449 E. coli isolates, 199 (44.3%) were identified as ESBL, with the highest prevalence in pus (35.6%) and urine (27.2%). ESBL‐producing E. coli isolates demonstrated high sensitivity (above 90%) to amoxicillin–clavulanic acid, ceftazidime, ertapenem, meropenem, and tigecycline. Our study also underlined the higher prevalence of multidrug resistance (MDR) in ESBL compared to non‐ESBL. The results highlight the urgent need for enhanced surveillance and infection control measures in healthcare settings to combat the spread of ESBL‐producing E. coli . Healthcare professionals, including nurses and clinicians, must be aware of this resistance pattern to guide empirical treatment choices and improve patient outcomes in managing infections caused by these resistant strains.
- 1 January 2025
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1) , 3743202
Open AccessA Cross‐Sectional Study of Extended‐Spectrum β ‐Lactamase–Producing Escherichia coli Isolated From Clinical Samples: Single‐Center Investigation in Indonesia
The emergence of extended‐spectrum beta‐lactamase–producing Escherichia coli (ESBL‐producing E. coli ) is a significant public health concern, particularly in developing countries like Indonesia, where reports on the prevalence and characteristics of these resistant strains are scarce. This lack of data hampers effective infection control and antibiotic stewardship efforts. This study is aimed at investigating the prevalence and assessing the antimicrobial susceptibility profiles of ESBL‐producing E. coli isolated from clinical samples of Indonesian patients, thereby contributing to an understanding of antibiotic resistance patterns in this region. A cross‐sectional study was conducted at RSUD dr. Adhyatma Hospital, Semarang, Indonesia, over 3 years (from January 2022 to December 2024). Clinical specimens were obtained from patients diagnosed with E. coli infections, and isolates were identified and assessed for antibiotic susceptibility utilizing the VITEK2 Compact system. Data were examined via the Fisher’s exact test. Out of 449 E. coli isolates, 199 (44.3%) were identified as ESBL, with the highest prevalence in pus (35.6%) and urine (27.2%). ESBL‐producing E. coli isolates demonstrated high sensitivity (above 90%) to amoxicillin–clavulanic acid, ceftazidime, ertapenem, meropenem, and tigecycline. Our study also underlined the higher prevalence of multidrug resistance (MDR) in ESBL compared to non‐ESBL. The results highlight the urgent need for enhanced surveillance and infection control measures in healthcare settings to combat the spread of ESBL‐producing E. coli . Healthcare professionals, including nurses and clinicians, must be aware of this resistance pattern to guide empirical treatment choices and improve patient outcomes in managing infections caused by these resistant strains.
- Open Access
- 25 December 2024
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 14 (1) , 104-111
Antibacterial efficacy of fruit extracts from three mangrove species: Rhizophora mucronata, Sonneratia alba, and Sonneratia caseolaris against multidrug-resistant (MDR) isolates derived from clinical specimens
Introduction: The emergence of multidrug-resistant (MDR) bacteria poses a significant challenge to public health, necessitating the exploration of alternative antimicrobial agents. This study investigates the antibacterial activity of fruit extracts from Rhizophora mucronata, Sonneratia alba, and Sonneratia caseolaris against MDR isolates derived from clinical specimens. Methods: Antibacterial activity was assessed against multiple multidrug-resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (A) strain sa1, vancomycin-resistant Enterococcus (VRE) strain ef1, carbapenem-resistant Pseudomonas aeruginosa (CRPAMRS) strain ps1, and extended-spectrum beta-lactamase (ESBL) Escherichia coli strain ec1. The antibacterial efficacy was determined using an agar-based well diffusion test to ascertain the zone of inhibition. Microdilution was assessed to ascertain the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values. Standard procedures were used to screen for plant phytochemicals (terpenoid, alkaloid, flavonoid, tannin, and saponin). Results: An ethanol extract of mangrove fruit exhibited antibacterial activity against MRSA, VRE, CRPA, and ESBL-Escherichia coli, producing an inhibitory zone diameter of 3-24 mm at 10 and 20 mg/mL, with MIC and MBC values exceeding 20 mg/mL. Specifically, Sonneratia alba was effective against MRSA and VRE with MIC and MBC values ≥10 mg/mL. Sonneratia caseolaris was effective against CRPA and ESBL-Escherichia coli with MIC and MBC values ≥5 mg/mL Phytochemical identification results showed the presence of terpenoids, alkaloids, flavonoids, tannins, and saponins in all three extracts. Conclusion: The fruit extracts examined have antibacterial activity against MDR isolates. Additional studies are required to isolate and characterize the specific bioactive substances that generate these effects.
- 25 December 2024
- Published by Maad Rayan Publishing Company in Journal of Herbmed Pharmacology
- Vol. 14 (1) , 104-111
Open AccessAntibacterial efficacy of fruit extracts from three mangrove species: Rhizophora mucronata, Sonneratia alba, and Sonneratia caseolaris against multidrug-resistant (MDR) isolates derived from clinical specimens
Introduction: The emergence of multidrug-resistant (MDR) bacteria poses a significant challenge to public health, necessitating the exploration of alternative antimicrobial agents. This study investigates the antibacterial activity of fruit extracts from Rhizophora mucronata, Sonneratia alba, and Sonneratia caseolaris against MDR isolates derived from clinical specimens. Methods: Antibacterial activity was assessed against multiple multidrug-resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus (A) strain sa1, vancomycin-resistant Enterococcus (VRE) strain ef1, carbapenem-resistant Pseudomonas aeruginosa (CRPAMRS) strain ps1, and extended-spectrum beta-lactamase (ESBL) Escherichia coli strain ec1. The antibacterial efficacy was determined using an agar-based well diffusion test to ascertain the zone of inhibition. Microdilution was assessed to ascertain the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values. Standard procedures were used to screen for plant phytochemicals (terpenoid, alkaloid, flavonoid, tannin, and saponin). Results: An ethanol extract of mangrove fruit exhibited antibacterial activity against MRSA, VRE, CRPA, and ESBL-Escherichia coli, producing an inhibitory zone diameter of 3-24 mm at 10 and 20 mg/mL, with MIC and MBC values exceeding 20 mg/mL. Specifically, Sonneratia alba was effective against MRSA and VRE with MIC and MBC values ≥10 mg/mL. Sonneratia caseolaris was effective against CRPA and ESBL-Escherichia coli with MIC and MBC values ≥5 mg/mL Phytochemical identification results showed the presence of terpenoids, alkaloids, flavonoids, tannins, and saponins in all three extracts. Conclusion: The fruit extracts examined have antibacterial activity against MDR isolates. Additional studies are required to isolate and characterize the specific bioactive substances that generate these effects.
- 20 November 2024
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
The Diversity of multidrug-resistant bacteria in bloodstream infection from Indonesia patients
Background: Multidrug-resistant bacteria cases are increasing globally, including in Indonesia. Bloodstream infection (Bacteremia) is a term that represents the presence of bacteria in patient blood. Blood cultures have become one of the most critically important and frequently performed in the clinical microbiology laboratory. Aim: to determine the prevalence of multidrug-resistant (MDR) bacterial isolates in bloodstream infection patients in Indonesia. Methods: Over three years (January 2020 to December 2022) a cross-sectional study was conducted at Tugurejo Hospital in Semarang, Indonesia, to collect 184 bacterial isolates from patients with bloodstream infections. The initial identification involves Gram staining and colony morphology assessment, biochemical assays, and antimicrobial susceptibility testing utilizing the VITEK®2 Compact system. Results: The most identified bacterial isolate was Staphylococcus aureus (73.9 %), followed by Klebsiella pneumoniae (10.9 %), Acinetobacter sp. (8.7 %), and Escherichia coli (6.4 %). The overall prevalence of MDR bacterial isolates was >80 %, with the highest resistance observed in Staphylococcus aureus to benzylpenicillin (91.2%), Klebsiella pneumoniae, and Escherichia coli to ampicillin (100 % and 91.9 %) and Acinetobacter sp. to Cefazolin (100 %). Conclusion: Our study revealed that the presence of MDR pathogens in Bloodstream Infection was noteworthy. The findings of this study would assist in the decision-making process regarding Bloodstream Infection treatment.
- 20 November 2024
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
The Diversity of multidrug-resistant bacteria in bloodstream infection from Indonesia patients
Background: Multidrug-resistant bacteria cases are increasing globally, including in Indonesia. Bloodstream infection (Bacteremia) is a term that represents the presence of bacteria in patient blood. Blood cultures have become one of the most critically important and frequently performed in the clinical microbiology laboratory. Aim: to determine the prevalence of multidrug-resistant (MDR) bacterial isolates in bloodstream infection patients in Indonesia. Methods: Over three years (January 2020 to December 2022) a cross-sectional study was conducted at Tugurejo Hospital in Semarang, Indonesia, to collect 184 bacterial isolates from patients with bloodstream infections. The initial identification involves Gram staining and colony morphology assessment, biochemical assays, and antimicrobial susceptibility testing utilizing the VITEK®2 Compact system. Results: The most identified bacterial isolate was Staphylococcus aureus (73.9 %), followed by Klebsiella pneumoniae (10.9 %), Acinetobacter sp. (8.7 %), and Escherichia coli (6.4 %). The overall prevalence of MDR bacterial isolates was >80 %, with the highest resistance observed in Staphylococcus aureus to benzylpenicillin (91.2%), Klebsiella pneumoniae, and Escherichia coli to ampicillin (100 % and 91.9 %) and Acinetobacter sp. to Cefazolin (100 %). Conclusion: Our study revealed that the presence of MDR pathogens in Bloodstream Infection was noteworthy. The findings of this study would assist in the decision-making process regarding Bloodstream Infection treatment.